Leading the world in developing novel implantable neurotechnologies

Through our successful bionic vision program, we have developed an advanced brain-machine interface with the potential to stimulate growth in Australian manufacturing of brain implant systems, and deliver improved health outcomes to patients with otherwise untreatable neurological conditions.

With support of MRFF Frontiers Stage 2 funding, we will create a commercial enterprise focused on providing sight to the blind and movement to paraplegics’ limbs, transforming healthcare for people with blindness and paralysis.

Beyond improving healthcare, commercial success will see the creation of new export opportunities, highly-skilled manufacturing and medical device design jobs, and economic growth for Australia.

Stage 2 MRFF Funding will:

  • Create and grow a successful neurotechnology business delivering bionic vision for the blind
  • Adapt and extend the capabilities of the current technology towards the creation of a device capable of restoring arm movement for people paralysed by spinal cord injury
  • Build a new manufacturing capacity and resilient supply chain capable of delivering a bionic vision system, centred on Monash Vision Group's implantable and wearable technologies
  • Accelerate the growth of our translation-focused neurobionics research program at Monash University, including the formation of new industry-focused academic partnerships
  • Develop new national capacity in clinical trials and long-term rehabilitation programs for recipients of implantable brain-machine and nervous system interfaces.

We are proud to be leading the world in developing novel implantable solutions for patients suffering neurological deficits and look forward to contributing further to advancements within this space.

We acknowledge past funding through the Australian Research Council’s Research in Bionic Vision Science and Technology Initiative (SRI 1000006), NHMRC, ARC, MRFF and the Center of Excellence for Integrative Brain Function.

We would like to thank Marc and Eva Besen, and Alan and Elizabeth Finkel for their generous donations to further discovery research on neurobionics.